Keywords: خط دوم درمان; AE; adverse event; ALK; anaplastic lymphoma kinase; aNSCLC; advanced non-small cell lung cancer; DRG; diagnosis-related group; EGFR; epidermal growth factor receptor; GLM; generalized linear model; HMO; health maintenance organization; HR; hazard ratio; I
مقالات ISI خط دوم درمان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: خط دوم درمان; Autoimmune Hepatitis; Azathioprine Intolerance; 6-Mercaptopurine; Second-Line Therapy; AIH; autoimmune hepatitis; CBR; complete biochemical remission; IBD; inflammatory bowel disease; MMF; mycophenolate mofetil; 6-MP; 6-mercaptopurine; PBC; primary biliar
Keywords: خط دوم درمان; Bevacizumab; ISG15 expression; Non-small-cell lung cancer; Refractory; Second-line therapy; Topotecan;
Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma
Keywords: خط دوم درمان; Costs of drugs; ESMO-MCBS; Randomized phase 3 trials; Second-line therapy; Survival;
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Keywords: خط دوم درمان; Advanced renal cell carcinoma; Immune checkpoint inhibitor; Immunotherapy agents; Nivolumab; Second-line therapy; PD-1 inhibitor;
An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer
Keywords: خط دوم درمان; Bladder cancer; Cisplatin resistance; Malaria protein; Second-line therapy; Targeted therapy;
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program
Keywords: خط دوم درمان; Type 2 diabetes; Longitudinal observational study; Treatment patterns; Second-line therapy; Outcomes; Real-world evidence;
Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study
Keywords: خط دوم درمان; Bevacizumab; Everolimus; mTOR inhibitor; Renal cell carcinoma; Second-line therapy; Sequential therapy
A randomised phase II study of pemetrexed versus pemetrexed + erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
Keywords: خط دوم درمان; Non-small cell lung cancer; Non-squamous; Second-line therapy; Pemetrexed; Erlotinib;
Use of second-line therapies for management of massive primary postpartum hemorrhage
Keywords: خط دوم درمان; Balloon tamponade; Hysterectomy; Primary postpartum hemorrhage; Second-line therapy; Uterine arterial embolization; Uterine compression suture
Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design
Keywords: خط دوم درمان; Advanced urothelial carcinoma; Prognostic factors; Response to prior chemotherapy; Second-line therapy
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer
Keywords: خط دوم درمان; Sagopilone; Non-small-cell lung carcinoma; Epothilones; Second-line therapy; Phase II study; Randomized
Second-line therapy in advanced biliary tract cancer: What should be the standard?
Keywords: خط دوم درمان; Biliary tract cancer; Second-line therapy; Chemotherapy; Salvage therapy; Progressive disease
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
Keywords: خط دوم درمان; Malignant pleural mesothelioma; Second-line therapy; Pemetrexed; Re-treatment; Progression-free survival; Disease control
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Keywords: خط دوم درمان; Advanced kidney cancer; mTOR inhibitor; RAD001; REACT; Safety; Second-line therapy
Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Keywords: خط دوم درمان; Angiogenesis; Non-small cell lung cancer; Tyrosine kinase inhibitor; Vascular disrupting agent; Second-line therapy
Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel
Keywords: خط دوم درمان; Prostate cancer; CRPC; Second-line therapy; Docetaxel; Targeted therapy
Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
Keywords: خط دوم درمان; Renal cell carcinoma; Tyrosine kinase inhibitor; Second-line therapy; Axitinib; Everolimus
Recommendations for the optimal management of early and advanced urothelial carcinoma
Keywords: خط دوم درمان; Urinary bladder cancer; Bladder carcinoma; Transitional cell carcinoma; Review literature; First-line therapy; Second-line therapy; Adjuvant; Neoadjuvant
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Keywords: خط دوم درمان; Malignant pleural mesothelioma; Second-line therapy; Pemetrexed; Re-treatment; Progression-free survival; Disease control
Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer: A Phase II Study
Keywords: خط دوم درمان; Gemcitabine; Maintenance; Non-small cell lung cancer; S-1; Second-line therapy
Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer
Keywords: خط دوم درمان; Non-small-cell-lung cancer; First-line therapy; Second-line therapy; Third-line therapy; Response; Progression free survival; Overall survival
Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
Keywords: خط دوم درمان; Cetuximab; Esophageal cancer; Second-line therapy
Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
Keywords: خط دوم درمان; Hormone-refractory prostate cancer; Second-line therapy; Docetaxel; Estramustine phosphate
Every-day clinical practice in patients with advanced non-small-cell lung cancer
Keywords: خط دوم درمان; Non-small-cell-lung cancer; First-line therapy; Second-line therapy; Third-line therapy; Systemic therapy; Radiotherapy; Observational study
Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer
Keywords: خط دوم درمان; Chemotherapy; Small cell lung cancer; Recurrent disease; Second-line therapy; Third-line therapy; Lomustine; Cyclophosphamide; Etoposide;
Therapy of small cell lung cancer with emphasis on oral topotecan
Keywords: خط دوم درمان; Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan
Second-line treatment for malignant pleural mesothelioma
Keywords: خط دوم درمان; Mesothelioma; Second-line therapy; Chemotherapy; Targeted therapy
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer
Keywords: خط دوم درمان; SCLC; Irinotecan; Gemcitabine; Second-line therapy
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients: The DISTAL-2 randomized trial
Keywords: خط دوم درمان; Non-small-cell lung cancer; Second-line therapy; Docetaxel; Gemcitabine; Vinorelbine; Capecitabine
Pemetrexed in the treatment of advanced non-squamous lung cancer
Keywords: خط دوم درمان; Pemetrexed; NSCLC; Non-squamous carcinoma; First-line therapy; Second-line therapy; Maintenance therapy; SCLC
Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy
Keywords: خط دوم درمان; Recurrent lung cancer; Gemcitabine; Docetaxel; Second-line therapy
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer
Keywords: خط دوم درمان; Advanced non-small cell lung cancer; Treatment strategy; First-line chemotherapy; Second-line therapy; Third-line therapy; Biological drugs;
Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer
Keywords: خط دوم درمان; Non-small cell lung cancer; Second-line therapy; Irinotecan; Cisplatin; Phase II study
Prise en charge des cancers bronchiques non à petites cellules après docétaxel-cisplatine
Keywords: خط دوم درمان; Cancer bronchique non à petites cellules; Traitement de première ligne; Docétaxel; Cisplatine; Traitement de deuxième ligne; Non-small cell lung carcinoma; First-line therapy; Docetaxel; Cisplatin; Second-line therapy;
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil
Keywords: خط دوم درمان; Second-line therapy; Relapsed; Refractory; Aggressive non-Hodgkin's lymphoma
Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer
Keywords: خط دوم درمان; Gemcitabine; Exisulind; Second-line therapy; Progressing non–small cell lung cancer
Effectiveness and Tolerability of Fulvestrant in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
Keywords: خط دوم درمان; Anastrozole; Antiestrogen; Hormonal therapy; Second-line therapy; Tamoxifen;
Current and Future Perspectives on Fulvestrant
Keywords: خط دوم درمان; Anastrozole; Antiestrogen; First-line therapy; Hormonal therapy; Second-line therapy;
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
Keywords: خط دوم درمان; Carboplatin; Gemcitabine; Platinum-containing combinations; Relapsed ovarian cancer; Second-line therapy;
A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy
Keywords: خط دوم درمان; Patient outcome; SCCHN; second-line therapy;